Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text

Alex Kavanagh; Richard Baverstock; Lysanne Campeau; Kevin Carlson; Ashley Cox; Duane Hickling; Genviève Nadeau; Lynn Stothers; Blayne Welk

doi:10.5489/cuaj.5912

Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text

Alex Kavanagh, Richard Baverstock, Lysanne Campeau, Kevin Carlson, Ashley Cox, Duane Hickling, Genviève Nadeau, Lynn Stothers, Blayne Welk

科研成果: 期刊稿件 › 文献综述 › 同行评审

42 引用（Scopus）

源语言	英语
页（从-至）	E157-E176
期刊	Journal of the Canadian Urological Association
卷	13
期	6
DOI	https://doi.org/10.5489/cuaj.5912
出版状态	已出版 - 2019
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学
泌尿学

访问文件

10.5489/cuaj.5912

其它文件与链接

引用此

Kavanagh, A, Baverstock, R, Campeau, L, Carlson, K, Cox, A, Hickling, D, Nadeau, G, Stothers, L & Welk, B 2019, 'Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text', Journal of the Canadian Urological Association, 卷 13, 号码 6, 页码 E157-E176. https://doi.org/10.5489/cuaj.5912

@article{9b97dedb1e1b44d09cc0602ae03d2d8e,

title = "Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text",

author = "Alex Kavanagh and Richard Baverstock and Lysanne Campeau and Kevin Carlson and Ashley Cox and Duane Hickling and Genvi{\`e}ve Nadeau and Lynn Stothers and Blayne Welk",

note = "Funding Information: Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs, and has received a research grant from Astellas. Dr. Baverstock has been a speaker for Allergan, Astellas, BSCI, and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Campeau has been an advisory board and speaker bureau member for Asetllas and Pfizer; has received grants/honoraria from Allergan, Astellas, and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Cox has been an advisory board member for Pfizer; a speakers bureau member for Astellas and Pfizer; has received grants/honoraria from Astellas and Pfizer; and has participated in clinical trials supported by Aquinox. Dr. Hickling has been an advisory board member for Pfizer; a speakers bureau member for Allergan, Astellas and Pfizer; has received grants/honoraria from Allergan, Astellas and Pfizer; and has participated in clinical trials supported by Astellas. Dr. Nadeau has been an advisory board member for Allergan, AMS, Astellas, Boston Scientific, Ferring, and Pfizer; a speakers bureau member for, Allergan, Astellas, Ferring Laborie, and Pfizer; and and has participated in clinical trials supported by Astellas. The remaining authors report no competing personal or financial interests related to this work.",

year = "2019",

doi = "10.5489/cuaj.5912",

language = "English",

volume = "13",

pages = "E157--E176",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "6",

}

TY - JOUR

T1 - Canadian Urological Association guideline

T2 - Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text

AU - Kavanagh, Alex

AU - Baverstock, Richard

AU - Campeau, Lysanne

AU - Carlson, Kevin

AU - Cox, Ashley

AU - Hickling, Duane

AU - Nadeau, Genviève

AU - Stothers, Lynn

AU - Welk, Blayne

N1 - Funding Information: Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs, and has received a research grant from Astellas. Dr. Baverstock has been a speaker for Allergan, Astellas, BSCI, and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Campeau has been an advisory board and speaker bureau member for Asetllas and Pfizer; has received grants/honoraria from Allergan, Astellas, and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Cox has been an advisory board member for Pfizer; a speakers bureau member for Astellas and Pfizer; has received grants/honoraria from Astellas and Pfizer; and has participated in clinical trials supported by Aquinox. Dr. Hickling has been an advisory board member for Pfizer; a speakers bureau member for Allergan, Astellas and Pfizer; has received grants/honoraria from Allergan, Astellas and Pfizer; and has participated in clinical trials supported by Astellas. Dr. Nadeau has been an advisory board member for Allergan, AMS, Astellas, Boston Scientific, Ferring, and Pfizer; a speakers bureau member for, Allergan, Astellas, Ferring Laborie, and Pfizer; and and has participated in clinical trials supported by Astellas. The remaining authors report no competing personal or financial interests related to this work.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85070925389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070925389&partnerID=8YFLogxK

U2 - 10.5489/cuaj.5912

DO - 10.5489/cuaj.5912

M3 - Review article

AN - SCOPUS:85070925389

SN - 1911-6470

VL - 13

SP - E157-E176

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 6

ER -